In Vitro Susceptibility Testing of Bedaquiline Against Mycobacterium abscessus Complex [Susceptibility]

We performed bedaquiline broth microdilution susceptibility using Clinical and Laboratory Standards Institute (CLSI) guidelines on 104 non-duplicate isolates of Mycobacterium abscessus complex [M. abscessus subsp. abscessus (76), M. abscessus subsp. massiliense (10), M. abscessus subsp. bolletii, (2) and M. abscessus subsp. abscessus/subsp. massiliense hybrid, i.e., M. abscessus subsp. abscessus by rpoB gene and subsp. massiliense by erm(41) gene (16)]. All isolates from patients not known to have been on prior bedaquiline had MIC values ≤0.25 µg/mL. The bedaquiline MIC₅₀ values for 76 isolates of M. abscessus subsp. abscessus and 16 isolates of M. abscessus subsp. abscessus/subsp. massiliense hybrid were 0.06 µg/mL. The MIC₅₀ and MIC₉₀ values for 10 isolates of M. abscessus subsp. massiliense were 0.12 µg/mL. Only two isolates of M. abscessus subsp. bolletii were tested with bedaquiline MICs of 0.06 µg/mL.

Our study suggests that oral bedaquiline may have potential use in treatment of disease caused by the M. abscessus complex. Combination therapy with other agents (imipenem, cefoxitin, amikacin, and/or tigecycline) is recommended.

https://ift.tt/2Qa7O5e